Nigeria’s pharmaceutical industry has faced mounting pressure from rising production costs, foreign exchange volatility, high financing expenses and dependence on imported raw materials. For listed drug manufacturers, navigating these challenges while protecting profitability and sustaining investor confidence has placed greater responsibility on their chief financial officers (CFOs).
Beyond overseeing financial reporting and regulatory compliance, these executives play critical roles in managing liquidity, securing financing, controlling operational costs and supporting expansion strategies in an increasingly competitive market.
Several pharmaceutical and healthcare companies listed on the Nigerian Exchange (NGX) have recorded significant increases in their market valuations, reflecting changing investor expectations and the financial performance of the sector.
From Fidson Healthcare and MeCure Industries to May & Baker and Neimeth International Pharmaceuticals, the finance executives behind these companies bring experience spanning investment banking, taxation, corporate finance and financial management.
Nairametrics profiles the finance executives of the largest pharmaceutical and healthcare-related companies listed on the NGX, ranked by market capitalisation as of October 23, 2026.
Osho Olaniyi Thomas is the Chief Financial Officer of Juli Plc, a Nigerian pharmaceutical and healthcare company listed on the Nigerian Exchange.
He is responsible for the company’s financial reporting and accounting oversight, supporting management in monitoring business performance and meeting its financial disclosure obligations.
Thomas is a Fellow of the Institute of Chartered Accountants of Nigeria and holds a Master of Business Administration degree, reflecting his professional background in accounting and business management.
His position as Chief Financial Officer is documented in Juli Plc’s 2024 audited financial statements and its financial reports for the first and second quarters of 2025.
He was among the executives who signed the company’s financial statements, providing formal accountability for its reported financial position and performance.
Juli Plc operates in the pharmaceutical distribution and healthcare sector, with activities including the wholesale and retail distribution of pharmaceutical products. Juli Plc recorded a 45.5% decline in revenue to N146.86 million in the first half of 2026, compared with N269.25 million in H1 2025.
Despite the revenue decline, the pharmaceutical distributor reduced its net loss by 59.2%, from N31.54 million to N12.86 million, largely through cost reductions.
The company’s market capitalisation currently stands at N1.31 billion
Nonye Offorjamah is the Head of Finance at Neimeth International Pharmaceuticals Plc, with over two decades of experience in financial management, accounting, taxation and corporate reporting.
She joined Neimeth in September 2024, following a six-month stint at Simba Group, where she served as Accounts and Tax Manager.
Before joining Simba Group, Offorjamah spent nearly 18 years at May & Baker Nigeria Plc, holding several finance-related positions. Between 2013 and 2024, she served as Subsidiary Operations Accountant and Tax Manager, overseeing financial reporting, tax compliance and regulatory audits. She previously worked as Accounts Payable Manager between 2008 and 2013.
Offorjamah began her professional career as a Tax Trainee at KPMG Nigeria in 2001.
She holds a Higher National Diploma in Accountancy from Ondo State Polytechnic, now Rufus Giwa Polytechnic, and has completed executive training at Lagos Business School.
She is a Fellow of the Institute of Chartered Accountants of Nigeria and an Associate Member of the Chartered Institute of Taxation of Nigeria.
Neimeth International Pharmaceuticals Plc recorded a 26% increase in revenue to N3.66 billion in the first half of 2026, compared with N2.91 billion in the corresponding period of 2025.
According to the company’s unaudited financial statements for the six months ended June 30, 2026, profit after tax increased marginally by 1.9% to N207.66 million, from N203.76 million in H1 2025.
As of October 23, 2026, Neimeth International Pharmaceuticals Plc had an estimated market capitalisation of N34.67 billion on the NGX
Ayodeji Aboderin is the Executive Director of Finance and Chief Financial Officer of May & Baker Nigeria Plc, a position he has held since January 2014.
With nearly three decades of experience in financial management, budgeting, business strategy and corporate reporting, Aboderin has built his career across Nigeria’s manufacturing, food and beverage, and pharmaceutical industries.
Before joining May & Baker, he served as Financial Controller at PZ Cussons Nigeria between July 2012 and December 2013. He previously spent over five years at Dansa Foods Limited, a subsidiary of the Dangote Group, as Head of Management Accounts.
His earlier career included nearly five years as a Budget and Finance Analyst at Nigerian Bottling Company, following six years as an Accountant at Standard Flour Mills Limited.
Aboderin holds a Higher National Diploma in Accountancy from The Polytechnic, Ibadan. In 2015, he received a professional excellence award from Top Executives publication.
As of October 23, 2026, May & Baker Nigeria Plc had a market capitalisation of approximately N68.58 billion on the Nigerian Exchange. May & Baker Nigeria Plc recorded a 51% increase in profit before tax to N4.85 billion in the first half of 2026, compared with N3.21 billion in the corresponding period of 2025.
According to the company’s unaudited financial statements for the six months ended June 30, 2026, the improved performance was driven primarily by cost reductions, stronger operating profitability and higher interest income.
Ifedamola Oluwasegun F. is the Group Chief Financial Officer of MeCure Group, overseeing the financial operations of MeCure Industries Plc and MeCure Healthcare Limited.
He assumed the position in December 2021, bringing experience in investment banking, trade finance, corporate strategy and capital management.
